- WuXi AppTec’s net income for the third quarter was 3.51 billion yuan, falling short of the estimated 3.67 billion yuan.
- The company reported revenue of 12.06 billion yuan, exceeding the estimate of 11.41 billion yuan.
- Earnings per share (EPS) for the quarter stood at 1.22 yuan.
- Analyst recommendations for WuXi AppTec include 24 buy ratings, 2 hold ratings, and no sell ratings.
A look at WuXi AppTec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
WuXi AppTec, a company specializing in manufacturing medical products, is poised for a promising long-term outlook based on its Smartkarma Smart Scores. With a solid score of 4 in Dividend, Growth, and Resilience, and a top-notch score of 5 in Momentum, the company is demonstrating strong performance in key areas essential for sustained success. These scores indicate that WuXi AppTec is showing robust growth potential, financial stability, and resilience in the face of market challenges, coupled with significant positive momentum.
Overall, WuXi AppTec’s Smartkarma Smart Scores suggest a positive trajectory for the company’s future prospects, aligning with its core operations in manufacturing biological products and providing related services. Investors may find WuXi AppTec an attractive opportunity for long-term investment due to its impressive scores across key factors essential for sustained growth and performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
